On the heels of sol­id tu­mor da­ta and with com­peti­tors surg­ing, Po­sei­da scraps au­tol­o­gous CAR-T in fa­vor of al­lo

Po­sei­da CEO Er­ic Os­tertag was not shy about the prospects he sees for au­tol­o­gous CAR-T ther­a­pies in the age of off-the-shelf al­ter­na­tives: They are “go­ing the way of the di­nosaur.”

His com­pa­ny is of­fi­cial­ly start­ing that piv­ot.

In its quar­ter­ly up­date, San Diego-based Po­sei­da an­nounced that it’s wind­ing down the P-BC­MA-101 au­tol­o­gous pro­gram, one of its for­mer leads, as part of a “planned strate­gic shift to al­lo­gene­ic BC­MA” — name­ly P-BC­MA-AL­LO1.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER